Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal-Survival-Cure Model
*Jeremy Taylor, University of Michigan 


For monitoring patients treated for prostate cancer, Prostate Specific Antigen (PSA) is measured periodically after they receive treatment. Increases in PSA are suggestive of recurrence of the cancer and are used in making decisions about possible new treatments. The data from studies of such patients typically consist of longitudinal PSA measurements, censored event times and baseline covariates. Methods for the combined analysis of both longitudinal and survival data have been developed in recent years, with the main emphasis being on modeling and estimation. We analyze data from a prostate cancer study in which the patients are treated with radiation therapy using a joint model. Here we focus on utilizing the model to make individualized prediction of disease progression for censored and alive patients, based on all their available pre-treatment and follow-up data. In this model the l

Print Friendly
For more information send email: ichps@amstat.orgHPSS 2005